Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulranumab monotherapy in osteoarthritis of the hip or knee
NCT02336698Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2015
- Primary completion
- Sep 2016
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 3 trial of fulranumab in osteoarthritis of the hip, knee osteoarthritis (OA), sponsored by Janssen Pharmaceutical. Started Jul 2015; status: completed.
02
Drugs
fulranumab
03
Conditions
osteoarthritis of the hipknee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT02336698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02336698.